Open AccessPD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications
Author(s) -
Natalie Wolkow,
Frederick A. Jakobiec,
Amir Afrogheh,
Martin Kidd,
Ralph C. Eagle,
Sara I. Pai,
William C. Faquin
Publication year - 2020
Publication title -
ophthalmic plastic and reconstructive surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.528
H-Index - 56
eISSN - 1537-2677
pISSN - 0740-9303
DOI - 10.1097/iop.0000000000001585
Subject(s) - adenoid cystic carcinoma , medicine , adenoid , immunohistochemistry , pathology , carcinoma , orbit (dynamics) , oncology , cancer research , aerospace engineering , engineering
To determine if there is a biologic rationale for using checkpoint inhibitor drugs targeting programmed cell death ligand 1 (PD-L1) and PD-L2 in the treatment of adenoid cystic carcinoma of the orbit.